Observational studyAlimentary pharmacology & therapeutics2020

Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease.

Matthew Bohm et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.